Severe sepsis, coagulation, and fibrinolysis: Dead end or one way?

Critical Care Medicine

Volumn 40, Issue 9, 2012, Pages 2704-2708

  Fourrier, François ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; THROMBIN ANTITHROMBIN COMPLEX;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL VIRULENCE; BINDING AFFINITY; BLOOD CLOTTING; CELL INVASION; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INNATE IMMUNITY; MORTALITY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; SEPSIS; THROMBIN TIME; YERSINIA;

ANTICOAGULANTS; CRITICAL CARE; CRITICAL ILLNESS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRINOLYSIS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; PROTEIN C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEPSIS; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 84865494488     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318258ff30     Document Type: Article

References (38)

1. Hardaway RM, Williams CH, Vasquez Y: Disseminated intravascular coagulation in sepsis. Semin Thromb Hemost 2001; 27: 577-583
2. Schouten M, Wiersinga WJ, Levi M, et al: Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83:536-545
3. Jourdain M, Carrette O, Tournoys A, et al: Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation. Am J Respir Crit Care Med 1997; 156:1825-1833
4. Chu AJ: Tissue factor, blood coagulation, and beyond: An overview. Int J Inflam 2011; 2011:367284
5. Roemisch J, Gray E, Hoffmann JN, et al: Antithrombin: A new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13:657-670
6. Rezaie AR: Regulation of the protein C anticoagulant and antiinflammatory pathways. Curr Med Chem 2010; 17:2059-2069
7. Abraham E, Reinhart K, Opal S, et al; OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290: 238-247
8. Warren BL, Eid A, Singer P, et al; KyberSept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
9. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
10. Loof TG, Mörgelin M, Johansson L, et al: Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011; 118:2589-2598
11. Bergmann S, Hammerschmidt S: Fibrinolysis and host response in bacterial infections. Thromb Haemost 2007; 98:512-520
12. Potempaa J, Pikeb RN: Corruption of innate immunity by bacterial proteases. J Innate Immun 2009; 1:70-87
13. Degen JL, Bugge TH, Goguen JD: Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 2007; 5 Suppl 1:24-31
14. Sun H, Wang X, Degen JL, et al: Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2009; 113:1358-1364
15. Luo D, Szaba FM, Kummer LW, et al: Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica. J Immunol 2011; 187:1866-1876
16. Borissoff JI, ten Cate H: From neutrophil extracellular traps release to thrombosis: An overshooting host-defense mechanism? J Thromb Haemost 2011; 9:1791-1794
17. Kipnis E, Guery BP, Tournoys A, et al: Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury. Shock 2004; 21:444-451
18. Robriquet L, Collet F, Tournoys A, et al: Intravenous administration of activated protein C in Pseudomonas-induced lung injury: Impact on lung fluid balance and the inflammatory response. Respir Res 2006; 7:41
19. Choi G, Hofstra JJ, Roelofs JJ, et al: Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007; 35:1362-1368
20. Niessen RW, Lamping RJ, Jansen PM, et al: Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 1997; 78:1088-1092
21. Hayakawa M, Sawamura A, Yanagida Y, et al: The response of antithrombin III activity after supplementation decreases in proportion to the severity of sepsis and liver dysfunction. Shock 2008; 30:649-652
22. Asakura H, Ontachi Y, Mizutani T, et al: Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol 2001; 67:170-175
23. Asakura H, Ontachi Y, Mizutani T, et al: An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med 2001; 29:1164-1168
24. Zenz W, Muntean W, Zobel G, et al: Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator. Thromb Haemost 1995; 74:802-803
25. Fourrier F, Chopin C, Goudemand J, et al: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101:816-823
26. Dhainaut JF, Shorr AF, Macias WL, et al: Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure. Crit Care Med 2005; 33:341-348
27. Shorr AF, Bernard GR, Dhainaut JF, et al: Protein C concentrations in severe sepsis: An early directional change in plasma levels predicts outcome. Crit Care 2006; 10:R92
28. Nevière R, Tournoys A, Mordon S, et al: Antithrombin reduces mesenteric venular leukocyte interactions and small intestine injury in endotoxemic rats. Shock 2001; 15:220-225
29. Faust SN, Levin M, Harrison OB, et al: Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:408-416
30. de Kleijn ED, de Groot R, Hack CE, et al: Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003; 31:1839-1847
31. Wunderink RG, Laterre PF, Francois B, et al; CAPTIVATE Trial Group: Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2011; 183:1561-1568
32. Dhainaut JF, Laterre PF, Janes JM, et al; Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: Data from the PROWESS trial. Intensive Care Med 2003; 29:894-903
33. Ely EW, Laterre PF, Angus DC, et al; PROWESS Investigators: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31:12-19
34. Wiedermann CJ, Kaneider NC: A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis 2006; 17:521-526
35. Kienast J, Juers M, Wiedermann CJ, et al; KyberSept investigators: Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4:90-97
36. Nadel S, Goldstein B, Williams MD, et al; REsearching severe Sepsis and Organ dysfunction in children: A gLobal perspective (RESOLVE) study group: Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 2007; 369:836-843
37. Fourrier F, Chopin C, Huart JJ, et al: Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104:882-888
38. Yamakawa K, Fujimi S, Mohri T, et al: Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: A historical control study. Crit Care 2011; 15:R123